Hansen Pharmaceutical(SZ:002412)2024-05-17 11:04Financial Performance - The company's undistributed profits for 2023 amount to 1.04 billion CNY [3] - Main product revenue for 2023: - Si Mo Tang oral liquid: 540 million CNY, a year-on-year increase of 1.23% - Tian Ma Xing Nao capsules: 161 million CNY, a year-on-year increase of 19.99% - Shuo Quan capsules: 83 million CNY, a year-on-year increase of 8.21% [3] - The three main products accounted for 81.98% of the company's total revenue in 2023 [5] Dividend and Shareholder Return - The company has not declared dividends for 2023, with profits being allocated to support daily operations and business development [3] - Future dividend plans will be disclosed in accordance with regulations, focusing on sustainable development while ensuring shareholder returns [4] Corporate Governance and Compliance - The company is actively implementing the new "National Nine Articles" to enhance governance and financial management [3] - There is a commitment to improving internal controls and preventing past issues from recurring [2] Product Development and Market Strategy - The company aims to enhance its core competitiveness by expanding the market for Si Mo Tang oral liquid and developing Tian Ma Xing Nao capsules as a leading brand [5] - Future capital expenditure plans will be based on market conditions and business needs [4] ESG and Social Responsibility - The company is committed to ESG principles and will continue to focus on corporate social responsibility [4]